|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
N/A
|
National Institutes of Health
|
|
Novel platform linking cancer-specific glycosylation with cell signaling outcomes
|
1R21CA229044-01
|
$225,250
|
ABBOTT, KAREN
|
UNIV OF ARKANSAS FOR MED SCIS
|
|
Master Regulatory MicroRNAs in Glioblastoma
|
5U01CA220841-02
|
$452,813
|
ABOUNADER, ROGER
|
UNIVERSITY OF VIRGINIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-05
|
$192,024
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-05
|
$20,853,800
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-05
|
$922,200
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systems
|
1R01CA227136-01A1
|
$454,956
|
AGHI, MANISH
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Mutagenesis and migration in glioblastoma cells
|
1R21CA220111-01A1
|
$179,240
|
AHN, EUN HYUN
|
UNIVERSITY OF WASHINGTON
|
|
Serum metabolomic profiling of glioma risk in the PLCO study
|
ZIA CP010152 10792
|
$52,848
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-05
|
$1,223,634
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Single-cell DNA methylation analysis of human cancer
|
ZIA BC 011846
|
$218,409
|
Aldape, Kenneth
|
CCR (NCI)
|
|
Development and validation of a predictor of meningioma recurrence
|
ZIA BC 011847
|
$72,803
|
Aldape, Kenneth
|
CCR (NCI)
|
|
Chemically produced neural progenitors as a delivery vehicle for anti-glioma therapy
|
1R43CA221490-01A1
|
$300,000
|
ALEXANIAN, ARSHAK
|
CELL REPROGRAMMING AND THERAPEUTICS, LLC
|
|
Chemically produced neural progenitors loaded with ferumoxide-protamine sulfate complex for visualization of gliomas
|
1R43CA228726-01A1
|
$300,000
|
ALEXANIAN, ARSHAK
|
CELL REPROGRAMMING AND THERAPEUTICS, LLC
|
|
Treatment of glioma with nanocombretastatin with MRI monitoring
|
5R01CA206190-03
|
$344,269
|
ALI, MESER
|
Henry Ford Health System
|
|
Oncohistones: Role of Histone H3 Mutations in the Oncogenesis of Pediatric Cancers
|
5P01CA196539-04
|
$1,855,117
|
ALLIS, CHARLES
|
ROCKEFELLER UNIVERSITY
|
|
Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics
|
5U01CA202144-04
|
$741,952
|
ALTER, ORLY
|
UNIVERSITY OF UTAH
|
|
Inherited bone marrow failure syndromes study
|
ZIA CP010144 07130
|
$1,652,758
|
Alter, Blanche
|
DCEG (NCI)
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$753,084
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
In vivo regulators of TERT promoter mutant glioblastoma
|
1F32CA228365-01
|
$58,654
|
AMEN, ALEXANDRA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
|
Developing Human Induced Pluripotent Stem Cell Precision Oncology Models
|
1R50CA233164-01
|
$155,981
|
ANASTASAKI, CORINA
|
WASHINGTON UNIVERSITY
|
|
A clones genomic stability as biomarker of its DNA-damage resilience
|
5K99CA215256-02
|
$166,644
|
ANDOR, NOEMI
|
STANFORD UNIVERSITY
|
|
Development of whole-brain in vivo 2HG imaging for precision medicine in mutant IDH glioma
|
5R01CA211080-02
|
$530,585
|
ANDRONESI, OVIDIU
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
5U10CA180828-05
|
$605,293
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Development of an MRI-compatible, High-Frequency Irreversible Electroporation (H-FIRE) System for Non-thermal Ablation of Inoperable Brain Tumors
|
1R43CA233158-01
|
$244,498
|
ARENA, CHRISTOPHER
|
VOLTMED, INC.
|
|
Natural History and Specimen Banking for Patients with CNS Tumors
|
ZIA BC 011768
|
$416,202
|
Armstrong, Terri
|
CCR (NCI)
|
|
Outcomes and Risk of Rare Tumors
|
ZIA BC 011837
|
$138,734
|
Armstrong, Terri
|
CCR (NCI)
|
|
NOB-018 Mouse Model of CNS Radiation-Induced Hypersomnia
|
ZIG BC 011836
|
$138,734
|
Armstrong, Terri
|
CCR (NCI)
|
|
Stanford Cancer Institute
|
3P30CA124435-11S1
|
$248,520
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
3P30CA124435-11S2
|
$171,518
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
5P30CA124435-11
|
$3,334,464
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-09S1
|
$249,371
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-09
|
$2,480,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant
|
2P30CA082103-19
|
$7,954,381
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S1
|
$84,000
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S2
|
$206,488
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S3
|
$257,838
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumors
|
5R01CA155769-07
|
$410,877
|
BADIE, BEHNAM
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Normal and Neoplastic Growth in the Brain
|
5P01CA096832-14
|
$1,999,508
|
BAKER, SUZANNE
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Cooperating Pathways in Gliomagenesis
|
5R01CA188516-05
|
$372,463
|
BAKER, SUZANNE
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating Cells
|
5R35CA197684-03
|
$848,325
|
BALDWIN, ALBERT
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Characterizing the resistance mechanisms to BET-bromodomain inhibition in MYC-amplified medulloblastoma
|
4R00CA201592-03
|
$249,000
|
BANDOPADHAYAY, PRATITI
|
DANA-FARBER CANCER INST
|
|
Functional Inhibition of Deubiquitylase HAUSP to Disrupt Glioblastoma Stem Cells
|
5R01CA184090-04
|
$362,569
|
BAO, SHIDENG
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Targeting Brain Tumor Stem Cells In The Hypoxic Microenvironment
|
5R01CA187780-04
|
$362,569
|
BAR, ELI
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Vesicular Stomatitis Virus (VSV) Replication in Malignant Cells
|
5R01CA194404-04
|
$334,911
|
BARBER, GLEN
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Studies of amplification in rhabdomyosarcoma
|
ZIA BC 011378
|
$358,849
|
Barr, Frederic
|
CCR (NCI)
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,537,925
|
Barr, Frederic
|
CCR (NCI)
|
|
Washington University/ Siteman Cancer Center Lead Academic Site
|
5U10CA180833-05
|
$1,394,352
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|